Published in Eur Heart J on January 25, 2005
Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol (2012) 2.03
Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology (2009) 1.83
Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol (2009) 1.46
Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats. PLoS One (2015) 1.39
New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension (2009) 1.28
Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut (2005) 1.23
Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol (2008) 1.20
Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res (2008) 1.14
ACE and ACE2: a tale of two enzymes. Eur Heart J (2005) 1.13
Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem (2008) 1.11
Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension (2013) 1.07
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm (2009) 1.05
Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol (2011) 1.04
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond) (2011) 0.97
Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol (2010) 0.96
Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. Drug Discov Today (2010) 0.96
ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep (2014) 0.92
Pathogenesis of diabetic nephropathy. J Diabetes Investig (2011) 0.91
Angiotensin-converting enzyme 2: the first decade. Int J Hypertens (2011) 0.90
Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci (Lond) (2010) 0.89
ACE2, angiotensin-(1–7), and Mas: the other side of the coin. Pflugers Arch (2013) 0.89
AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity. PLoS One (2014) 0.87
Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev (2012) 0.85
Effects of ACE2 inhibition in the post-myocardial infarction heart. J Card Fail (2010) 0.85
From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol (2014) 0.85
New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One (2014) 0.84
Cardiovascular effects of losartan and its relevant clinical application. Curr Med Chem (2009) 0.84
Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy. PLoS One (2014) 0.83
Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS One (2013) 0.83
Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. PLoS One (2012) 0.81
Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting. Exp Ther Med (2014) 0.81
Low birth weight activates the renin-angiotensin system, but limits cardiac angiogenesis in early postnatal life. Physiol Rep (2015) 0.79
Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. J Card Fail (2013) 0.78
ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. J Cardiovasc Pharmacol (2015) 0.77
Angiotensin peptides and nitric oxide in cardiovascular disease. Antioxid Redox Signal (2012) 0.77
Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J (2005) 0.77
Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res (2016) 0.77
ACE2-Ang (1-7) axis is induced in pressure overloaded rat model. Int J Clin Exp Pathol (2015) 0.76
Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease. PLoS One (2016) 0.76
Myofibroblast secretome and its auto-/paracrine signaling. Expert Rev Cardiovasc Ther (2016) 0.75
Arg972 Insulin receptor substrate-1 is associated with decreased serum angiotensin-converting enzyme 2 levels in acute myocardial infarction patients: in vivo and in vitro evidence. Cardiovasc Diabetol (2013) 0.75
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. PLoS One (2017) 0.75
Interference with the renin-angiotensin system in heart failure. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.75
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med (2003) 7.74
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes (2008) 4.13
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
A common fold mediates vertebrate defense and bacterial attack. Science (2007) 3.43
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Mechanisms of diabetic complications. Physiol Rev (2013) 3.41
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 3.00
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes (2007) 2.51
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes (2009) 2.34
Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med (2013) 2.29
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension (2007) 2.13
Antitumor effects in gastrointestinal stromal tumors using photodynamic therapy with a novel glucose-conjugated chlorin. Mol Cancer Ther (2014) 2.10
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension (2003) 2.10
Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol (2011) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes (2010) 1.95
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 1.95
Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension (2006) 1.90
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol (2006) 1.88
E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes (2010) 1.85
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res (2012) 1.78
Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation (2007) 1.74
Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem (2005) 1.73
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens (2003) 1.70
The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust (2006) 1.68
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes (2004) 1.67
Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int (2011) 1.63
Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 1.59
Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol (2004) 1.58
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int (2010) 1.57
GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct Mol Biol (2007) 1.56
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 1.51
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol (2007) 1.49
Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension (2004) 1.49
UKPDS and the legacy effect. N Engl J Med (2008) 1.49
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) (2012) 1.49
Digoxin in heart failure and cardiac arrhythmias. Med J Aust (2003) 1.47
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens (2002) 1.45
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med (2012) 1.44
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. Hypertension (2012) 1.43
Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 1.40
ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab (2004) 1.40
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens (2005) 1.40
Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem (2005) 1.39
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation (2004) 1.38
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc Res (2002) 1.38
ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes (2008) 1.36
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes (2002) 1.36
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol (2005) 1.35
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J (2003) 1.33
Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol (2003) 1.32
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol (2004) 1.28
Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation (2002) 1.27
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care (2013) 1.26
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J (2005) 1.25
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol (2004) 1.23
The X-ray crystal structure of full-length human plasminogen. Cell Rep (2012) 1.22
Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy. Diabetes (2011) 1.22
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int (2004) 1.19
A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care (2002) 1.17
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol (2010) 1.16
Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol (2007) 1.16
Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol (2004) 1.15
Beta-amino acids: versatile peptidomimetics. Curr Med Chem (2002) 1.15